Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2692621 | 1.00 | KMT2A (0.56) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL19976423 | 1.00 | KMT2A (0.56) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL12754596 | 1.00 | KMT2A (0.56) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL200621 | 1.00 | KMT2A (0.56) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL3486991 | 1.00 | KMT2A (0.56) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL10075962 | 1.00 | KMT2A (0.56) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL20747758 | 0.91 | KMT2A (0.57) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL468538 | 0.91 | KMT2A (0.57) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL1294423 | 0.89 | MEN1 (0.52) | KMT2AMEN1L3MBTL1MAPTCYP3A4 | |
| SCHEMBL15508101 | 0.84 | KMT2A (0.56) | KMT2AMEN1L3MBTL1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9005906-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005906-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140315979-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315979-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8796437-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796437-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2188298-B1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440803-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2010091308-A2 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009023855-A2 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | HNRNPH1, RNASEH1, SNRPE | KMT2A 2072/4885MEN1 3569/4885L3MBTL1 295/4885 |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | KMT2A 3144/4885MEN1 4122/4885L3MBTL1 367/4885 |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | KMT2A 3144/4885MEN1 4122/4885L3MBTL1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.